• According to the American Cancer Society, cancer is the second leading cause of death globally.
• Oncology drugs are a cornerstone of modern cancer treatment.
• Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments.

Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.

According to the American Cancer Society, cancer is the second leading cause of death globally, with 2,001,140 new cancer cases and 611,720 cancer deaths projected to occur in the United States in 2024 (https://ibn.fm/JA0DN). Approximately one in six deaths worldwide is due to cancer. The global cancer burden is expected to rise to 28.4 million cases by 2040, a 47% increase from 2020. This surge is driven by population growth, aging, and lifestyle factors such as tobacco use, poor diet, and physical inactivity.

Among the most prevalent and deadly forms of cancer are lung cancer, which is responsible for 1.8 million deaths annually, making it the leading cause of cancer-related mortality (https://ibn.fm/woQzB); colorectal cancer, which accounts for nearly 935,000 deaths each year (https://ibn.fm/ms7ty); breast cancer, the most commonly diagnosed cancer, with more than 2.3 million new cases annually (https://ibn.fm/O313h); and stomach and liver cancers, which account for approximately 968,784 (https://ibn.fm/zyWfM) and 866,136 deaths per year, respectively (https://ibn.fm/4EvTp).

These statistics highlight the enormous need for effective cancer treatments, especially for high-mortality cancers such as glioblastoma (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and certain types of lung cancer.

Oncology drugs are a cornerstone of modern cancer treatment. These drugs range from traditional chemotherapy to targeted therapies and immunotherapies, which aim to enhance the body’s immune response against cancer cells. Oncology drugs play a vital role in:

• Extending Survival: Many advanced therapies have significantly improved survival rates for cancers once considered untreatable.
• Improving Quality of Life: Targeted treatments and immunotherapies often come with fewer side effects than traditional chemotherapy, allowing patients to maintain a better quality of life.
• Personalized Medicine: Advances in genetic testing have enabled the development of personalized oncology drugs tailored to the unique genetic makeup of a patient’s tumor.

The global oncology drug market was valued at approximately $158 billion in 2022 and is projected to reach $327 billion by 2037, reflecting a compound annual growth rate (“CAGR”) of 7.5% (https://ibn.fm/xBVyH). However, despite these advances, significant gaps remain in treatment efficacy, accessibility, and affordability, underscoring the urgent need for continued innovation.

Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Their unique approach leverages antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. Calidi’s therapeutic strategy centers on harnessing the power of antitumor virotherapies, which are engineered to selectively infect and destroy cancer cells while sparing healthy tissue.

To enhance the delivery and efficacy of these viruses, Calidi uses extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms to protect the virotherapy from the body’s immune system during administration. The company’s dual approach offers multiple advantages, including targeted tumor destruction, in which viruses directly attack cancer cells, leading to their destruction; and immune system activation, a process that triggers a systemic immune response and trains the immune system to recognize and attack cancer cells throughout the body.

Calidi’s robust pipeline includes three key product candidates:

• RTNova (“CLD-400”): Targeting lung cancer and metastatic cancer, RTNova is a systemic platform that can be administered intravenously. The technology includes a vaccinia virus enveloped with a human cell membrane designed to protect the viral payload from the body’s immune system during administration and home in on cancer cells.
• SuperNova (“CLD-201”): Targeting solid tumors such as head and neck, triple-negative breast cancer and soft tissue sarcoma, SuperNova combines mesenchymal stem cells with vaccinia viruses. This therapy aims to overcome the limitations of traditional treatments by directly targeting tumors and activating the immune system.
• NeuroNova (“CLD-101”): This therapy is designed for patients with glioblastoma and other high-grade gliomas. It utilizes neural stem cells to deliver antitumor viruses directly to brain tumors, offering a promising new approach for one of the most aggressive and treatment-resistant cancers.

Calidi is also developing next-generation engineered antitumor viruses to broaden the scope of cancers treatable with its platform.

The groundbreaking work being done by Calidi Biotherapeutics has the potential to transform the oncology drug market and significantly improve cancer care. By focusing on high-need cancer types such as GBM, TNBC, sarcoma and lung cancer, Calidi addresses critical gaps in current treatment options. The company’s innovative therapies not only aim to improve survival rates but also reduce the debilitating side effects associated with many existing cancer treatments. As Calidi’s products advance through clinical trials, they hold the promise of offering new hope to patients facing some of the most challenging cancers.

The global burden of cancer continues to grow, making the need for effective oncology drugs more pressing than ever. As a leader in innovative cancer treatment, Calidi Biotherapeutics is poised to play a pivotal role in shaping the future of oncology drug development. Its pioneering therapies represent a new frontier in the fight against cancer, offering hope for improved outcomes and a better quality of life for millions of patients worldwide.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• The company’s six-month revenue reached $20.1 million CAD ($14.15 million USD), reflecting steady long-term growth despite seasonal fluctuations.
• Gross profit margin increased to 29.2%, up from 18.4% in the prior year, signaling improved margins.
• Assets surged 372% to $185.3 million CAD ($130.47 million USD) during the six month period, following the acquisition of Solar Flow-Through Funds Ltd.
• Recent $70.3 million CAD ($49.5 million USD) deal with Qcells will drive revenue in upcoming quarters.
• Share price more than doubled in early February, signaling investor interest.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., posted its fiscal 2025 second-quarter results, emphasizing its six-month revenue of $20.1 million CAD ($14.15 million USD) and improved gross margins. According to the Q2 results, the company’s gross profit rose to $5.9 million CAD ($4.15 million USD) (or 29.2% of revenues), from $4.8 million CAD ($3.38 million USD) in 2024, reflecting a shift toward higher-margin business lines (https://ibn.fm/F30Jw).

Additionally, independent power producer (“IPP”) revenue increased from CAD $0.14 million ($0.07 million USD) to $5.4 million CAD ($3.8 million USD) during the same six-month period, with assets growing 372% to $185.3 million CAD ($130.47 million USD) following the acquisition of Solar Flow-Through Funds Ltd., as compared to $39.2 million CAD ($27.6 million USD) on June 30, 2024. The company ended the second quarter of fiscal 2025 with $33.6 million CAD ($23.66 million USD) in current assets, as compared to $17.6 million CAD ($12.39 million USD) in current assets as of year-end June 30, 2024. The increase is principally the result of the closing of the Solar Flow-Through Funds acquisition.

In addition to the encouraging Q2 results, the company’s stock saw a sharp rally in early February, rising from $3.86 CAD ($2.72 USD) on Jan. 31 to $9.08 CAD ($6.39 USD) by Feb. 10. While the price has since stabilized, the spike suggests growing investor interest in the company’s strategic direction and upcoming projects (https://ibn.fm/ZiPvC).

Beyond the current financials report, SolarBank is positioning itself for sustained expansion moving forward, recently securing additional major financing and strategic partnerships:

• $70.3 million CAD ($49.5 million USD) transaction with Qcells to sell and construct four solar projects in New York, with revenues to be recognized in future quarters (https://ibn.fm/QOyJY). The projects will utilize high-quality Qcells modules that will be manufactured in the U.S. The deal is part of the nearly $2.8 billion USD being invested by Qcells to boost U.S. domestic solar manufacturing and innovation to support and accelerate the U.S. clean energy transition.
• $25.8 million CAD ($18.17 million USD) project finance facility from RBC to develop two battery energy storage systems (“BESS”) in Ontario, a sector with strong long-term growth potential. Representing the company’s first foray into the battery storage sector, construction on the first project, SFF-06, began during the Feb. 10 week (https://ibn.fm/5WEhQ).
• 145 MW of solar projects in the pipeline, expected to reach notice to proceed within the next 12 months.

These projects reinforce SolarBank’s focus on securing stable, recurring revenue streams, including independent power production.

CEO Richard Lu acknowledged that seasonal factors affected Q2 revenue, a common trend in the solar industry, especially in winter months. However, higher-margin power production and asset growth offset the slight decline, leading to improved overall gross profits. “This is stable recurring revenue that is under long-term contracts, and we will continue to grow this business as evidenced by the $25.8 million Royal Bank of Canada debt facility that supports the construction of the BESS projects that we own,” Lu said.

The CEO also pointed out that delays in EPC (engineering, procurement, and construction) revenue were expected, as the company focused on securing a strong development partner. The Qcells deal, finalized at the end of the quarter, means these revenues will now be reflected in the coming periods, he added.

SolarBank’s strong asset growth, rising profit margins, and new revenue streams from power production and storage projects position the company well for continued success. With a robust project pipeline and investor interest reflected in the recent stock price rally, SolarBank sees itself well-positioned for sustained growth in the renewable energy market.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward looking information. Please refer to https://finance.yahoo.com/news/solarbank-announces-second-quarter-results-120000457.html and the press release referenced in this article for additional details on the nature, assumptions and risk factors associated with this forward looking information.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• Manufacturing within the U.S. offers numerous benefits that can significantly impact a company’s operational efficiency and market competitiveness
• The Massimo Group’s recent announcement highlights the company’s proactive approach in leveraging these benefits
• “We are committed to providing our customers with the highest quality golf carts while ensuring long-term business sustainability,” states the CEO

In recent years, manufacturing goods in the United States has become increasingly advantageous for companies aiming to enhance quality control, reduce lead times and navigate complex international trade dynamics. Recent tariff announcements have made the move to U.S. soil even more compelling. Massimo Group (NASDAQ: MAMO), a prominent player in the powersports industry, has exemplified this trend by announcing the relocation of its MVR Golf Cart series production to its Garland, Texas, facility (https://ibn.fm/34Aav). This strategic move not only underscores the benefits of domestic manufacturing but also aligns with the company’s vision of delivering superior products while adapting to evolving market conditions.

Manufacturing within the U.S. offers numerous benefits that can significantly impact a company’s operational efficiency and market competitiveness. One of the primary advantages is enhanced quality control. By situating production facilities domestically, companies can closely monitor manufacturing processes, ensuring that products meet stringent quality standards. This proximity facilitates immediate oversight and swift response to any issues that may arise during production, thereby maintaining high-quality outputs.

Another notable benefit is the reduction in lead times. Domestic manufacturing eliminates the lengthy shipping durations associated with overseas production. This reduction not only accelerates the time-to-market for products but also enables companies to respond more rapidly to market demands and consumer needs. Shorter lead times can lead to increased customer satisfaction and a more agile supply chain.

Furthermore, manufacturing in the U.S. can result in decreased costs, including tariff and delivery charges. Producing goods closer to the consumer reduces transportation expenses, which can be a significant portion of a product’s overall cost. Lower delivery costs can enhance a company’s profitability and offer competitive pricing advantages in the marketplace.

Massimo Group’s recent announcement highlights the company’s proactive approach in leveraging these benefits. In response to U.S. trade regulators imposing countervailing duties and antidumping tariffs on certain foreign manufacturers accused of unfair trade practices, Massimo has decided to shift the production of its MVR Golf Cart series to its existing facility in Garland, Texas. This decision is aimed at enhancing quality control and strengthening the company’s presence in the U.S. market.

“We are committed to providing our customers with the highest quality golf carts while ensuring long-term business sustainability,” said David Shan, CEO of Massimo Motor. “Bringing production to our Texas facility strengthens our supply chain, enhances quality assurance and positions us competitively in the U.S. market. Our customers and dealer partners can continue to rely on Massimo for innovative and reliable personal transportation solutions.”

By relocating production domestically, Massimo is poised to mitigate the financial impact of international tariffs and duties. This move not only safeguards the company from potential cost increases associated with imported goods but also aligns with a broader trend of reshoring manufacturing operations to the United States. Reshoring can provide companies with greater control over their supply chains and reduce exposure to global trade uncertainties.

The Massimo Group has established itself as a significant entity in the powersports sector. The company’s product portfolio includes a range of off-road vehicles, such as all-terrain vehicles (“ATVs”), utility task vehicles (“UTVs”), and golf carts. By focusing on innovation and quality, Massimo has cultivated a reputation for delivering reliable and high-performance vehicles tailored to diverse consumer needs.

The company’s vision centers on providing exceptional products that enhance the recreational and professional experiences of its customers. By prioritizing quality and customer satisfaction, Massimo aims to be a leader in the powersports industry, continually adapting to market trends and consumer preferences.

For more information, visit the company’s website at massimomotor.com, massimomarine.com and massimoelectric.com

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

• As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes.
• Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor.
• The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors.

Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and treatment. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer.

According to studies, GBM is the most common and aggressive primary brain tumor in adults (https://ibn.fm/55xHJ). Despite treatment, the median survival time is approximately 12 to 15 months, with a five-year survival rate of less than 7%. TNBC accounts for about 10–15% of all breast cancers (https://ibn.fm/gR3FS) and is characterized by its lack of estrogen, progesterone, and HER2 receptors, making it unresponsive to some of the most effective therapies. It tends to grow and spread faster than other breast cancers, with fewer treatment options and a poorer prognosis.

Lung cancer is the second most common cancer in both men and women in the United States (https://ibn.fm/xSbgu). In 2024, an estimated 234,580 new cases will be diagnosed, and approximately 125,070 people will die from the disease. The five-year survival rate remains low, emphasizing the need for improved therapeutic strategies.

In the face of these challenges, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving outcomes for patients with these and other cancers. Their approach leverages cutting-edge science to enhance the body’s natural defenses against cancer.

Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells. To enhance the delivery and efficacy of these viruses, Calidi employs patented technologies (extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms) designed to protect the virotherapy from the immune system until it reaches the tumor site. This method not only facilitates direct tumor destruction but also stimulates an immune response against cancer cells throughout the body.

Calidi’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Its pipeline includes RTNova, SuperNova and NeuroNova.

RTNova is a systemic platform that can be administered intravenously to target lung cancer and metastatic cancers. The technology includes a vaccinia virus enveloped with a human cell membrane designed to protect the viral payload from the body’s immune system during administration and home in on cancer cells.

Aimed at treating solid tumors, SuperNova combines mesenchymal stem cells with antitumor vaccinia virus to target and destroy cancer cells. This approach holds potential for addressing cancers such as head & neck, TNBC and soft tissue sarcoma, where conventional treatments have limited efficacy.

NeuroNova is a product designed for patients with newly diagnosed and recurrent high-grade gliomas, including GBM. NeuroNova utilizes neural stem cells engineered to deliver antitumor viruses directly to the tumor site. The therapy is advancing into Phase 1b/2 clinical trials, reflecting promising results.

Calidi Biotherapeutics’ innovative therapies have the potential to revolutionize cancer treatment by enhancing efficacy, stimulating immune response and addressing unmet needs. For cancers such as GBM, head & neck, TNBC, sarcoma and lung cancer, where current treatments are often inadequate, Calidi’s approach offers promising new potential.

The pressing need for effective treatments for these aggressive cancers underscores the importance of innovative research and development in oncology. Calidi Biotherapeutics’ pioneering work in harnessing the power of antitumor viruses and its patented technologies designed to protect the viral payload from the body’s immune system during administration represents significant advancements in the fight against these deadly diseases. As Calidi’s therapies progress through clinical trials, there is hope for improved outcomes and survival rates for patients facing these challenging cancers.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• D-Wave’s Qubits 2025 quantum computing user conference will be held in Scottsdale, Arizona, March 31 and April 1, as well as a virtual livestream of the first day’s talks.
• The event will feature presentations from D-Wave executives, customers and industry thought leaders, highlighting product and technical roadmap updates, scientific advancements, the intersection of quantum and AI, and more.
• Presentations will showcase how the company’s quantum technology is delivering tangible value today.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first supplier of production-grade quantum computers, announced that its Qubits 2025 quantum computing user conference will be held in Scottsdale, Arizona, on March 31 and April 1. This year’s event, themed “Quantum Realized,” will feature presentations from D-Wave executives, customers and industry thought leaders, showcasing how the company’s quantum technology solutions are delivering tangible value today. It also serves as an important component of the company’s recently launched integrated brand campaign of the same name (https://ibn.fm/HXHqu).

Speakers will share groundbreaking work based on their use of D-Wave quantum technology to solve problems today, including D-Wave customers Davidson Technologies, Jülich Supercomputing Centre (Forschungszentrum Jülich), Japan Tobacco, Momentum Worldwide, NTT DOCOMO, Pusan National University, Quantum Research Sciences, SAS, the University of Southern California’s Viterbi School of Engineering, and more.

Qubits 2025 will feature:

• D-Wave’s latest quantum innovations, product roadmap and vision for advancing quantum technology,
• The latest groundbreaking quantum research underway from labs and universities around the world using D-Wave^TM technology,
• Recent developments at the intersection of quantum and AI,
• Talks and live demonstrations showcasing real-world quantum applications across logistics and manufacturing, government, life sciences, financial services, and more, and
• Breakout sessions with D-Wave technical advisors to help participants fast track their quantum journey.

Those unable to attend the event in person will be able to register for and access a free livestream of the first day’s talks on the Qubits website (https://ibn.fm/xs2jS).

A premier event for the global quantum community and organizations interested in realizing value from today’s quantum computers, Qubits 2025 comes at a time when quantum computing is quickly moving from experimentation to applications in production, amid a growing need for businesses, governments and scientific organizations to understand how to leverage the technology to address challenges that are beyond the reach of classical computers.

The event’s theme and D-Wave brand campaign, “Quantum Realized,” aims to demonstrate that quantum computing is not just a theoretical future breakthrough—it is delivering value right now via D-Wave technology that is solving complex problems for industries including logistics, retail, manufacturing, and more. According to D-Wave CEO Dr. Alan Baratz, quantum is here, now, and D-Wave’s quantum technology is helping businesses, researchers and governments address their most computationally complex problems today.

“Qubits 2025 is an incredible opportunity to engage with the trailblazing innovators at the center of this quantum transformation,” Dr. Baratz said. “It’s a must-attend event for anyone looking to harness the remarkable power of this technology to strengthen business operations, achieve new scientific breakthroughs, and capitalize on the beneficial relationship between quantum and AI.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage^TM quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2^TM systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

• Shifting to value-based care improves patient outcomes and cost-effective provider efficiency.
• Adageis’ ProActive Care shifts focus from reactive treatment to preventive, patient-centered care, with AI-driven analytics identifying high-risk patients and addressing care gaps.
• Patients receive more personalized, effective treatment, rather than a volume treatment driven approach.
• Better patient outcomes lead to reduced hospitalizations and cost savings, while increased cost monitoring and efficiency for providers supports increased revenue and net income potential.

For many patients, the American healthcare system often feels rushed, transactional and fragmented. Doctors have limited time, and treatment decisions can be driven by billing structures rather than patient well-being.

The traditional fee-for-service model rewards volume—more tests, more procedures, more appointments—without necessarily improving patient outcomes. This system can lead to unnecessary or ineffective treatments, frustrating patients and increasing provider administrative burdens. A shift toward value-based care, supported by AI-driven solutions like Adageis’ ProActive Care platform, offers an alternative: focusing on preventive care, coordination and long-term health outcomes rather than isolated visits and reactive treatments.

For providers, Adageis offers AI-centric software solutions for a range of healthcare organizations, increasing operational cost effectiveness, identifying key revenue opportunities, as well as actionable strategies for growth.

The company’s data-driven approach enables providers to identify high-risk patients before complications arise, track patient health trends in real time, coordinate care effectively to reduce hospital readmissions, and ensure compliance with value-based care metrics to unlock financial incentives.

With seamless integration into major electronic health record (“EHR”) systems like AthenaHealth, Cerner and Epic, Adageis’ solutions enhance efficiency without disrupting provider workflows.

For patients, the ProActive Care model means:

• Early intervention: AI-driven risk analysis spots potential health issues before they become serious.
• Less fragmentation: Providers coordinate across specialties, reducing redundant tests and miscommunications.
• Fewer hospital visits: Continuous monitoring prevents avoidable complications.
• More time with doctors: Automated data insights allow providers to focus on patient needs, not administrative tasks.

This leads to better overall health outcomes and a higher quality of life—patients spend more time staying healthy and less time managing chronic conditions in emergency rooms and hospitals.

Shifting to a value-based model benefits not just patients, but also healthcare organizations. When done correctly, this approach improves operational efficiency and financial performance by optimizing care team workflows, reducing administrative waste, meeting government and insurance incentives for quality-based care, and enhancing patient satisfaction and retention, leading to better long-term financial stability.

The shift to value-based, proactive healthcare is gaining traction, but many providers struggle with implementation. Technology-driven solutions like Adageis’ ProActive Care help bridge that gap by providing the data and tools needed to make the transition seamless and financially viable. For patients, this means a system that prioritizes well-being over volume. For providers, it offers financial sustainability, improved operational efficiency, and greater income potential. With AI-driven risk analysis, providers can focus resources on patients who need the most attention, ensuring higher reimbursement rates for quality care metrics.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• Rising cancer numbers indicate urgent need for advancements in cancer research, and stem cell research is rising to meet the challenge.
• Stem cells are being explored not only as a tool to regenerate damaged tissues but also as a delivery vehicle for innovative cancer treatments.
• Calidi Biotherapeutics stands at the forefront of integrating stem cell technology into oncology.

As 2025 approaches, cancer continues to be one of the most significant global health challenges. Projections indicate a sharp increase in cancer diagnoses, with new cases in 2024 expected to surpass 2 million annually in the United States for the first time. Globally, cancer incidence is expected to climb, driven by factors such as aging populations, lifestyle changes and environmental exposures. Lung, breast and colorectal cancers remain among the most prevalent, accounting for a significant portion of cases worldwide. Furthermore, rising rates of colorectal and cervical cancers among younger age groups highlight the shifting demographics of cancer incidence.

These numbers indicate the urgent need for advancements in cancer research, and stem-cell research is rising to meet the challenge. Companies operating in the space, such as Calidi Biotherapeutics (NYSE American: CLDI), could make significant headway in both diagnosing and treating the disease that runs rampant around the world.

Amid the concerning trend of increasing cancer numbers, advancements in stem-cell research offer renewed hope. Stem cells are being explored not only as a tool to regenerate damaged tissues but also as a vehicle for innovative cancer treatments. For example, mesenchymal stem cells (“MSCs”) can be engineered to deliver anti-cancer agents directly to tumor sites, minimizing damage to healthy cells. Furthermore, stem cells have shown potential in boosting immune-system responses and enabling personalized therapies tailored to individual genetic profiles.

The ability of stem cells to repair damage from cancer treatments such as chemotherapy and radiation further underscores their significance. They are particularly promising in combating side effects such as organ toxicity and tissue damage, improving the overall quality of life for cancer patients. By leveraging stem-cell technology, researchers are exploring more-effective, less-invasive solutions to prevent and treat various cancers.

Calidi Biotherapeutics stands at the forefront of integrating stem cell technology into oncology (https://ibn.fm/XNCku). The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem cells, their therapeutic potential is significantly amplified. Stem cells can shield and potentiate the viruses, enhancing their delivery to tumors and prolonging their therapeutic action.

Calidi’s pipeline includes the proprietary SuperNova (“SNV”) platform, which utilizes allogeneic adipose-derived mesenchymal stem cells (“AD-MSCs”) as carriers for antitumor virotherapy (https://ibn.fm/jH5TU). This approach has shown promise in preclinical studies and safety studies, with potential applications for hard-to-treat cancers such as head & neck, triple negative breast and soft tissue sarcoma. Additionally, their NeuroNova platform is designed to treat aggressive brain tumors. These innovative platforms exemplify Calidi’s commitment to transforming cancer treatment using advanced biotechnology.

In 2024, Calidi achieved key milestones that position it as a leader in stem cell-based cancer therapies (https://ibn.fm/BSBUQ). The company secured critical funding to advance its clinical trials and expanded its partnerships with leading academic institutions. Its clinical pipeline progressed significantly, with preparations for FDA-regulated trials demonstrating the safety and efficacy of its therapies.

Looking ahead, Calidi aims to bring its innovative treatments to market, potentially revolutionizing the way cancers are managed and treated. By continuing to refine its stem cell platforms and exploring new applications, the company is poised to make significant contributions to oncology.

The projected rise in cancer cases highlights the urgent need for transformative approaches to prevention and treatment. Stem cell research, with its multifaceted potential, offers a beacon of hope in this fight. Companies such as Calidi Biotherapeutics are not only advancing the science but also translating these breakthroughs into tangible therapies that could redefine cancer care. As we move into 2025, the integration of stem cell technology into oncology could be a game-changer, offering renewed hope to millions worldwide.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

• $25.8 million financing from the Royal Bank of Canada will be used for a 4.99 MW Ontario-based battery energy storage system consisting of two projects, SFF-06 and 903.
• The projects mark SolarBank’s first foray into energy storage, a market expected to reach $31.2 billion USD by 2029.
• The project benefits from a 22-year contract with Ontario’s electricity operator, ensuring stable revenue.
• SolarBank is leveraging government incentives, including a 30% Clean Technology Investment Tax Credit.
• Anvil Crawler Development Corp. was awarded a $1.85 million contract for civil and electrical work on the project.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced that construction began on its first battery energy storage system (“BESS”) in Ontario during the week of February 10, 2025 (https://ibn.fm/smENa).

The project, known as SFF-06, is located in Cramahe, Ontario, and represents SolarBank’s entry into the fast-growing battery storage sector. The project will store energy to help balance the electrical grid and improve reliability.

The move comes as battery storage demand surges, with the global market projected to reach $31.2 billion USD by 2029, growing at 16.3% annually (https://ibn.fm/65lyd). Battery storage systems are becoming critical for addressing grid inefficiencies, aging infrastructure, and surging energy demand driven primarily by sectors such as artificial intelligence and crypto mining. 

The project is part of a $25.8 million financing package from Royal Bank of Canada, covering two SolarBank projects (SFF-06 and 903).

SolarBank holds a 50% stake in the 4.99 MW project through ProjectCo, a company formed after SolarBank’s $45 million acquisition of Solar Flow-Through Funds Ltd. in 2024. The remaining 50% is owned by a First Nations partnership, showcasing a commitment to Indigenous investment in renewable energy.

The project benefits from a 22-year contract awarded by Ontario’s Independent Electricity System Operator (“IESO”) under its Expedited Long-Term RFP (“E-LT1 RFP”) program.

• The contract provides a fixed capacity payment of $1,221 per megawatt per business day—well above the market average.
• SolarBank expects the project to have 4.74 MW of daily contract capacity for 251 business days per year.

This long-term agreement ensures stable revenue, making the project attractive for investors. Additionally, SolarBank is taking advantage of Canada’s Clean Technology Investment Tax Credit, which provides up to 30% reimbursement for capital costs on new clean energy projects. This significantly improves the project’s financial viability, making it a cost-effective expansion into energy storage.

SolarBank has awarded Anvil Crawler Development Corp. a $1.85 million contract for civil and electrical work on the project. Anvil Crawler is part of Skyline Group, which manages over $5.4 billion USD in assets.

With the project’s February construction startup, SolarBank is quickly implementing this strategic expansion into energy storage, which aligns with ongoing broader trends in renewable energy and grid modernization. The move is a natural extension of the company’s significant renewable energy expertise, with its impressive portfolio of renewable energy initiatives, including more than 100 megawatts of developed capacity and a pipeline exceeding one gigawatt, all positioning it as a key player in driving the renewable energy transition.

For more information, visit the company’s website at SolarBankCorp.com.

This report contains forward looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• NEWTON GOLF Company operates in a large and expanding global golf equipment market with rising demand for high-performance products.
• The company benefits from strong gross margins and a clear pathway to profitability as it scales its operations.
• U.S.-based manufacturing provides strict quality control, supply chain efficiency, and faster response times to market demand.
• An omnichannel sales strategy, including retail, e-commerce, and international distribution, enhances market reach and revenue diversification.
• Future growth opportunities include new product lines, strategic acquisitions, and continued technological advancements in golf equipment.

NEWTON GOLF (NASDAQ: SPGC), a Sacks Parente company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (“ULBP”) technology, weight-forward Center-of-Gravity (“CG”) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, NEWTON GOLF is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

NEWTON GOLF Company is headquartered in Camarillo, California.

Products

NEWTON GOLF is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (“ULBP”) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All NEWTON GOLF products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

NEWTON GOLF’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

For more information, visit the company’s website at https://newtongolfco.com.

NOTE TO INVESTORS: The latest news and updates relating to SPGC are available in the company’s newsroom at http://ibn.fm/SPGC

• SuperCom is a best-in-class developer of electronic monitoring (“EM”) technology that serves a variety of client needs, and primary focus on the growing market for court-supervised individuals under house arrest or restricted movement orders
• SuperCom’s PureSecurity Suite of solutions includes a number of compatible products, with key advantages that provide discreetly wearable functionality, GPS and RFID signal tracking, alert notifications to law enforcement and potential individual targets, along with superior battery life
• The company recently reported that a European government client has called for a sharp increase in orders over the initial contract expectations for SuperCom’s PureTrack GPS units, tripling the product’s unit orders over the past year
• SuperCom anticipates a 400% growth in PureTrack orders from this client by the end of the year

Electronic monitoring (“EM”) technology developer SuperCom’s (NASDAQ: SPCB) focus on building quality into its products for the public safety sector is reaping rewards as government entities in Europe and North America form a growing list of clients.

Last month, the company received new orders from an existing client, tripling the number of PureTrack GPS units they use year-over-year. PureTrack is part of SuperCom’s PureSecurity EM Suite of products for monitoring inmates and individuals under house arrest or other court-ordered rehabilitation programs.

The 200% growth in unit orders came as a European government customer sharply increased its demand for the EM tracking technology over original contract expectations. “We are excited to see rapid unit growth within this valuable nationwide European EM project,” SuperCom President and CEO Ordan Trabelsi stated (https://ibn.fm/t8SeD). “When numbers grow beyond what is originally expected, we see it as a clear signal to the effectiveness of our technology solutions and complimentary services.”

The PureSecurity suite provides court programs the capacity to free select convicts or accused suspects from prison or jail while still preserving safety for local communities. Compliance with the terms of house arrest and limited community movement for medical, educational or employment purposes can be remotely monitored in real-time to ensure court-established boundaries are not breached.

Because of EM’s value in reducing budgetary expenses and its potential for increasing rehabilitation and reducing criminal recidivism, its use is growing worldwide (https://ibn.fm/pcmh8).

The PureTrack GPS tracking device for enrollees in the electronic monitoring program can pair with other SuperCom suite devices such as the wearable PureOne monitor, the PureTag wearable RFID bracelet, and the home base station PureCom to provide a range of options from in-home detention, one-piece movement tracking, and EM tracking that provides boundary breach alerts not only to law enforcement but identified potential victims as well, teaming with simple smartphone accessibility.

The company’s suite of products has proven competitive within the global market, thanks largely to innovative features that include smartphone integration, anti-tamper mechanisms, fingerprint biometrics, voice communication, and extended battery life.

SuperCom’s announcement adds that with the growth of PureTrack orders beyond what was originally contracted, the company anticipates orders will pass 400% growth by the end of the year as part of “a large ongoing Nationwide European” EM project’s expansion.

“As we continue expanding our customer base in the U.S., we remain deeply committed to serving our existing customers with excellence — including key partners like this European government client,” Trabelsi stated.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB